Patents by Inventor Pei-Hua LIN
Pei-Hua LIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230265150Abstract: The present invention provides a fusion protein, comprising a chemokine polypeptide, which is a chemokine or a receptor binding domain thereof; and a cytokine polypeptide connected to said chemokine polypeptide, which is an interleukin, a TNF-superfamily cytokine or a receptor-binding domain thereof; wherein the chemokine polypeptide and the cytokine polypeptide have a common target cell, and the fusion protein has an improved chemokine activity as compared to the chemokine polypeptide, and an improved cytokine activity as compared to the cytokine polypeptide.Type: ApplicationFiled: March 17, 2023Publication date: August 24, 2023Applicant: NATIONAL CHUNG HSING UNIVERSITYInventors: Shiow-Her CHIOU, Kuan-Chih CHOW, Jui-Hung SHIEN, Yi-Hsin FAN, Pei-Hua LIN, Pei-Shan WU
-
Patent number: 11685783Abstract: Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: April 29, 2021Date of Patent: June 27, 2023Assignee: Shanghai Henlius Biotech Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Patent number: 11618786Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: January 25, 2022Date of Patent: April 4, 2023Assignee: Shanghai Henlius Biotech Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Publication number: 20220144955Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: January 25, 2022Publication date: May 12, 2022Applicant: Shanghai Henlius Biotech Inc.Inventors: Weidong JIANG, Pei-Hua LIN, Chi-Ling Tseng
-
Patent number: 11274155Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: April 10, 2019Date of Patent: March 15, 2022Assignee: Shanghai Henlius Biotech Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Patent number: 11261255Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.Type: GrantFiled: February 6, 2020Date of Patent: March 1, 2022Assignee: Shanghai Henlius Biotech, Inc.Inventors: Weidong Jiang, Pei-Hua Lin
-
Publication number: 20210277122Abstract: Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: April 29, 2021Publication date: September 9, 2021Applicant: Shanghai Henlius Biotech Inc.Inventors: Weidong JIANG, Pei-Hua LIN, Chi-Ling Tseng
-
Patent number: 11028173Abstract: Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: March 13, 2019Date of Patent: June 8, 2021Assignee: Shanghai Henlius Biotech, Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Publication number: 20200223929Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.Type: ApplicationFiled: February 6, 2020Publication date: July 16, 2020Inventors: Weidong JIANG, Pei-Hua LIN
-
Patent number: 10584171Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.Type: GrantFiled: May 29, 2015Date of Patent: March 10, 2020Assignee: Henlix Biotech Co., Ltd.Inventors: Wei-Dong Jiang, Pei-Hua Lin
-
Publication number: 20190270788Abstract: The present invention provides a fusion protein, comprising a chemokine polypeptide, which is a chemokine or a receptor binding domain thereof; and a cytokine polypeptide connected to said chemokine polypeptide, which is an interleukin, a TNF-superfamily cytokine or a receptor-binding domain thereof; wherein the chemokine polypeptide and the cytokine polypeptide have a common target cell, and the fusion protein has an improved chemokine activity as compared to the chemokine polypeptide, and an improved cytokine activity as compared to the cytokine polypeptide.Type: ApplicationFiled: May 17, 2019Publication date: September 5, 2019Applicant: NATIONAL CHUNG HSING UNIVERSITYInventors: Shiow-Her Chiou, Kuan-Chih Chow, Jui-Hung Shien, Yi-Hsin Fan, Pei-Hua Lin, Pei-Shan Wu
-
Publication number: 20190225691Abstract: Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: April 10, 2019Publication date: July 25, 2019Applicant: Shanghai Henlius Biotech Inc.Inventors: Weidong JIANG, Pei-Hua LIN, Chi-Ling TSENG
-
Publication number: 20190218295Abstract: Provided are anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-1 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-PD-1 antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: ApplicationFiled: March 13, 2019Publication date: July 18, 2019Applicant: Shanghai Henlius Biotech Inc.Inventors: Weidong Jiang, Pei-Hua Lin, Chi-Ling Tseng
-
Patent number: 10336801Abstract: The present invention provides a fusion protein, comprising a chemokine polypeptide, which is a chemokine or a receptor binding domain thereof; and a cytokine polypeptide connected to said chemokine polypeptide, which is an interleukin, a TNF-superfamily cytokine or a receptor-binding domain thereof; wherein the chemokine polypeptide and the cytokine polypeptide have a common target cell, and the fusion protein has an improved chemokine activity as compared to the chemokine polypeptide, and an improved cytokine activity as compared to the cytokine polypeptide.Type: GrantFiled: July 25, 2017Date of Patent: July 2, 2019Assignee: NATIONAL CHUNG HSING UNIVERSITYInventors: Shiow-Her Chiou, Kuan-Chih Chow, Jui-Hung Shien, Yi-Hsin Fan, Pei-Hua Lin, Pei-Shan Wu
-
Publication number: 20180193456Abstract: Provided are anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-VEGFR2 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-VEGFR2 antibodies and antigen binding fragments thereof. Also provided are related pharmaceutical compositions comprising anti-VEGFR2 antibodies (or antigen binding fragments thereof) and methods of their use in the treatment of pathological conditions characterized by excessive angiogenesis.Type: ApplicationFiled: June 29, 2016Publication date: July 12, 2018Inventors: Wei-Dong JIANG, Pei-Hua LIN, Chi-Ling TSENG
-
Publication number: 20170327554Abstract: The present invention provides a fusion protein, comprising a chemokine polypeptide, which is a chemokine or a receptor binding domain thereof; and a cytokine polypeptide connected to said chemokine polypeptide, which is an interleukin, a TNF-superfamily cytokine or a receptor-binding domain thereof; wherein the chemokine polypeptide and the cytokine polypeptide have a common target cell, and the fusion protein has an improved chemokine activity as compared to the chemokine polypeptide, and an improved cytokine activity as compared to the cytokine polypeptide.Type: ApplicationFiled: July 25, 2017Publication date: November 16, 2017Applicant: NATIONAL CHUNG HSING UNIVERSITYInventors: Shiow-Her CHIOU, Kuan-Chih CHOW, Jui-Hung SHIEN, Yi-Hsin FAN, Pei-Hua LIN, Pei-Shan WU
-
Publication number: 20170218073Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.Type: ApplicationFiled: May 29, 2015Publication date: August 3, 2017Inventors: Wei-Dong JIANG, Pei-Hua LIN